February 28, 2023 06:45 AM EST

AstraZeneca expands Canada R&D work, to add 500 jobs

Drew Armstrong

Executive Editor

AstraZeneca will expand its Canada R&D footprint, expanding its center near Toronto and creating a new rare diseases research center there with its Alexion unit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca expands Canada R&D work, to add 500 jobs

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

As­traZeneca ex­pands Cana­da R&D work, to add 500 jobs

Drew Armstrong

Executive Editor

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

AstraZeneca expands Canada R&D work, to add 500 jobs

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A